Kleo Pharmaceuticals to Present Preclinical Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in the Treatment of Multiple Myeloma at the 2020 American Society of Clinical Oncology Virtual Meeting

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing